Mutant-selective degradation by BRAF-targeting PROTACs

Hundreds of BRAF mutations have been identified in patients with cancer but currently approved drugs only target BRAF V600 mutants. Here, the authors develop a vemurafenib-based PROTAC that induces degradation of all classes of BRAF mutants without affecting wild-type RAF proteins.

Bibliographic Details
Main Authors: Shanique Alabi, Saul Jaime-Figueroa, Zhan Yao, Yijun Gao, John Hines, Kusal T. G. Samarasinghe, Lea Vogt, Neal Rosen, Craig M. Crews
Format: Article
Language:English
Published: Nature Portfolio 2021-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-21159-7
_version_ 1818754050001207296
author Shanique Alabi
Saul Jaime-Figueroa
Zhan Yao
Yijun Gao
John Hines
Kusal T. G. Samarasinghe
Lea Vogt
Neal Rosen
Craig M. Crews
author_facet Shanique Alabi
Saul Jaime-Figueroa
Zhan Yao
Yijun Gao
John Hines
Kusal T. G. Samarasinghe
Lea Vogt
Neal Rosen
Craig M. Crews
author_sort Shanique Alabi
collection DOAJ
description Hundreds of BRAF mutations have been identified in patients with cancer but currently approved drugs only target BRAF V600 mutants. Here, the authors develop a vemurafenib-based PROTAC that induces degradation of all classes of BRAF mutants without affecting wild-type RAF proteins.
first_indexed 2024-12-18T05:17:05Z
format Article
id doaj.art-c199e2f0eb92437a873d93ab5b38d197
institution Directory Open Access Journal
issn 2041-1723
language English
last_indexed 2024-12-18T05:17:05Z
publishDate 2021-02-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj.art-c199e2f0eb92437a873d93ab5b38d1972022-12-21T21:19:45ZengNature PortfolioNature Communications2041-17232021-02-0112111110.1038/s41467-021-21159-7Mutant-selective degradation by BRAF-targeting PROTACsShanique Alabi0Saul Jaime-Figueroa1Zhan Yao2Yijun Gao3John Hines4Kusal T. G. Samarasinghe5Lea Vogt6Neal Rosen7Craig M. Crews8Department of PharmacologyMolecular, Cellular, and Developmental Biology, Yale UniversityProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer CenterProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer CenterMolecular, Cellular, and Developmental Biology, Yale UniversityMolecular, Cellular, and Developmental Biology, Yale UniversityMolecular, Cellular, and Developmental Biology, Yale UniversityProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer CenterDepartment of PharmacologyHundreds of BRAF mutations have been identified in patients with cancer but currently approved drugs only target BRAF V600 mutants. Here, the authors develop a vemurafenib-based PROTAC that induces degradation of all classes of BRAF mutants without affecting wild-type RAF proteins.https://doi.org/10.1038/s41467-021-21159-7
spellingShingle Shanique Alabi
Saul Jaime-Figueroa
Zhan Yao
Yijun Gao
John Hines
Kusal T. G. Samarasinghe
Lea Vogt
Neal Rosen
Craig M. Crews
Mutant-selective degradation by BRAF-targeting PROTACs
Nature Communications
title Mutant-selective degradation by BRAF-targeting PROTACs
title_full Mutant-selective degradation by BRAF-targeting PROTACs
title_fullStr Mutant-selective degradation by BRAF-targeting PROTACs
title_full_unstemmed Mutant-selective degradation by BRAF-targeting PROTACs
title_short Mutant-selective degradation by BRAF-targeting PROTACs
title_sort mutant selective degradation by braf targeting protacs
url https://doi.org/10.1038/s41467-021-21159-7
work_keys_str_mv AT shaniquealabi mutantselectivedegradationbybraftargetingprotacs
AT sauljaimefigueroa mutantselectivedegradationbybraftargetingprotacs
AT zhanyao mutantselectivedegradationbybraftargetingprotacs
AT yijungao mutantselectivedegradationbybraftargetingprotacs
AT johnhines mutantselectivedegradationbybraftargetingprotacs
AT kusaltgsamarasinghe mutantselectivedegradationbybraftargetingprotacs
AT leavogt mutantselectivedegradationbybraftargetingprotacs
AT nealrosen mutantselectivedegradationbybraftargetingprotacs
AT craigmcrews mutantselectivedegradationbybraftargetingprotacs